Nu-Med Plus, Inc. (OTC: NUMD)

Nu-Med Plus, Inc. is a medical device company focused on developing, manufacturing, and marketing technologies utilizing nitric oxide for medical applications. The company creates nitric oxide generating formulations and delivery systems designed for use in hospitals, clinical settings, and research environments. Its primary goal is to provide innovative solutions that improve existing medical procedures by addressing unmet needs identified by healthcare professionals.

Nu-Med Plus, Inc. generates revenue through the development and planned commercialization of its nitric oxide-based products. The company intends to sell its nitric oxide generating formulation, hospital delivery device, clinical unit, portable rechargeable device, disposable units, and research dilution system once they receive regulatory approval. Revenue will be derived from direct sales of these medical devices and associated consumables to healthcare providers and research institutions.

The company operates through the following segments:

• Nitric Oxide Formulation: This segment focuses on creating a proprietary compound that generates nitric oxide gas on demand without relying on compressed gas cylinders. The formulation aims to produce medical-grade nitric oxide with minimal nitrogen dioxide impurities. It is intended for use across all delivery systems developed by the company.

• Hospital Delivery Device: This segment involves a bedside system designed for use in hospital intensive care units to deliver inhaled nitric oxide at therapeutic levels. The device includes controls and safety monitors to ensure precise dosing up to 40 ppm via ventilator integration. It features concentration monitoring, flow regulation, and gas purity safeguards as standard components.

• Clinical Delivery Unit: This segment provides a wall-powered unit for use in medical offices, clinics, and rehabilitation centers. Administration of nitric oxide is delivered via nasal cannula or non-rebreather face mask. The system is designed for ease of use in outpatient settings to support patient treatment outside of acute care environments.

• Portable Rechargeable Device: This segment offers a compact, mobile system with a rechargeable battery pack for use in areas with limited or unreliable power access. The device can be recharged via electrical outlets, solar arrays, or other alternative energy sources. It functions as a low-power, fully functional inhalation therapy device suitable for patient transport or remote deployment.

• Disposable Unit: This segment includes a single-use device designed to deliver a therapeutic dose of nitric oxide before being destroyed after use. It is intended for high-volume scenarios such as pandemics where sterilization between patients is impractical. The unit ensures infection control by preventing cross-contamination through destruction after each use.

• Research Dilution System: This segment features a patent-pending technology that dilutes pure nitric oxide from a pressurized tank with air or inert gases to produce concentrations from 1 to 500 ppm. The system is designed for investigational applications in laboratory settings. It provides high-purity nitric oxide for research purposes prior to potential clinical adoption.

Nu-Med Plus, Inc. operates in a niche within the medical device industry focused on nitric oxide delivery systems. The company faces limited direct competition due to the specialized nature of its technology, though it references the existing market dominance of products like Inomax for inhaled nitric oxide in neonatal care. Its competitive advantage lies in developing a lower-cost, on-site nitric oxide generation method that could reduce dependency on expensive gas cylinder logistics.

Nu-Med Plus, Inc. intends to serve hospitals, health systems, medical clinics, rehabilitation centers, and research laboratories globally. The company targets healthcare providers requiring inhaled nitric oxide therapy and research institutions investigating novel applications of the gas. Specific customer names are not disclosed in the filing, but the intended user base includes institutions engaged in neonatal care, pulmonary treatment, infectious disease management, and biomedical research.